Arovella Therapeutics Limited E4NA.F Stock
Arovella Therapeutics Limited Price Chart
Arovella Therapeutics Limited E4NA.F Financial and Trading Overview
| Arovella Therapeutics Limited stock price | 0.07 EUR |
| Previous Close | 0.02 EUR |
| Open | 0.02 EUR |
| Bid | 0.02 EUR x N/A |
| Ask | 0.03 EUR x N/A |
| Day's Range | 0.02 - 0.02 EUR |
| 52 Week Range | 0.0085 - 0.05 EUR |
| Volume | 90 EUR |
| Avg. Volume | 0 EUR |
| Market Cap | 21.4M EUR |
| Beta (5Y Monthly) | -0.830268 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.01 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
E4NA.F Valuation Measures
| Enterprise Value | 12.02M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 12.577542 |
| Price/Book (mrq) | 3.9166665 |
| Enterprise Value/Revenue | 7.062 |
| Enterprise Value/EBITDA | -1.584 |
Trading Information
Arovella Therapeutics Limited Stock Price History
| Beta (5Y Monthly) | -0.830268 |
| 52-Week Change | 100.00% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.05 EUR |
| 52 Week Low | 0.0085 EUR |
| 50-Day Moving Average | 0.03 EUR |
| 200-Day Moving Average | 0.02 EUR |
E4NA.F Share Statistics
| Avg. Volume (3 month) | 0 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 849.91M |
| Float | 536.56M |
| Short Ratio | N/A |
| % Held by Insiders | 17.74% |
| % Held by Institutions | 10.99% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:25 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -452.81% |
| Gross Margin | 83.47% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -67.43% |
| Return on Equity (ttm) | -178.93% |
Income Statement
| Revenue (ttm) | 1.7M EUR |
| Revenue Per Share (ttm) | 0.003 EUR |
| Quarterly Revenue Growth (yoy) | 6222.89% |
| Gross Profit (ttm) | 88.75K EUR |
| EBITDA | -7587677 EUR |
| Net Income Avi to Common (ttm) | -8569763 EUR |
| Diluted EPS (ttm) | -0.01 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 3.51M EUR |
| Total Cash Per Share (mrq) | 0.005 EUR |
| Total Debt (mrq) | 37.08K EUR |
| Total Debt/Equity (mrq) | 0.87 EUR |
| Current Ratio (mrq) | 2.526 |
| Book Value Per Share (mrq) | 0.006 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -6634886 EUR |
| Levered Free Cash Flow (ttm) | -5107283 EUR |
Profile of Arovella Therapeutics Limited
| Country | Germany |
| State | WA |
| City | Osborne Park |
| Address | 55 Howe Street |
| ZIP | 6017 |
| Phone | 61 8 6142 5555 |
| Website | https://www.arovella.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat short-term insomnia, which is marketed under the brand name of Ambien or Stilnox; invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer; OroMist, an oro-mucosal technology that delivers a range of drug classes through the cheeks, gums, tongue, or floor of the mouth; and Anagrelide to treat cancer. The company also develops oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Q&A For Arovella Therapeutics Limited Stock
What is a current E4NA.F stock price?
Arovella Therapeutics Limited E4NA.F stock price today per share is 0.07 EUR.
How to purchase Arovella Therapeutics Limited stock?
You can buy E4NA.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Arovella Therapeutics Limited?
The stock symbol or ticker of Arovella Therapeutics Limited is E4NA.F.
Which industry does the Arovella Therapeutics Limited company belong to?
The Arovella Therapeutics Limited industry is Biotechnology.
How many shares does Arovella Therapeutics Limited have in circulation?
The max supply of Arovella Therapeutics Limited shares is 1.14B.
What is Arovella Therapeutics Limited Price to Earnings Ratio (PE Ratio)?
Arovella Therapeutics Limited PE Ratio is now.
What was Arovella Therapeutics Limited earnings per share over the trailing 12 months (TTM)?
Arovella Therapeutics Limited EPS is -0.01 EUR over the trailing 12 months.
Which sector does the Arovella Therapeutics Limited company belong to?
The Arovella Therapeutics Limited sector is Healthcare.